Horizon Pharma (HZNP) Tops Q2 EPS by 17c, Revenues Beat; Offers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Horizon Pharma (HZNP) Tops Q2 EPS by 17c, Revenues Beat; Offers FY18 Revenue Outlook

Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focu

August 8, 2018 7:00 AM EDT

-- Record Quarterly Orphan and Rheumatology Segment Net Sales of $201.7 Million Increased 17 Percent; Represented 67 Percent of Total Company Net Sales --

-- Second-Quarter 2018 KRYSTEXXA® Net Sales Growth of 53 Percent; Continue to Expect Full-Year 2018 Net Sales Growth of More Than 65 Percent --

-- Target Enrollment Reached in Teprotumumab Phase 3 Clinical Trial, Significantly Ahead of Schedule --

-- Second-Quarter 2018 Net Sales of $302.8 Million; Second-Quarter 2018 GAAP Net Loss of $32.8 Million; Adjusted EBITDA of $116.8 Million --

-- Confirming Full-Year 2018 Net Sales Guidance Range of $1.170 Billion to $1.200 Billion;... More